Shares of InflaRx (IFRX) climbed more than 30% in extended trading on Wednesday, following positive results of the open-label extension part of the Company's international phase IIb study of IFX-1 in patients with moderate to severe Hidradenitis Suppurativa, dubbed SHINE.
from RTT - Biotech https://ift.tt/2NPTA5s
via IFTTT
No comments:
Post a Comment